Clinical application of antiangiogenic therapy: Microvessel density, what it does and doen't tell us

Journal of the National Cancer Institute

Volumn 94, Issue 12, 2002, Pages 883-893

  Hlatky, Lynn ^a   Hahnfeldt, Philip ^a   Folkman, Judah ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b s Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; THALIDOMIDE; TUMOR MARKER;

CANCER; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DENSITY; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MEASUREMENT; MICROVASCULATURE; MULTIPLE MYELOMA; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STRATIFICATION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; HUMANS; MICROCIRCULATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0037134709     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (136)

1. Tumor angiogenesis: A quantitative method for histologic grading
2. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma
3. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma
4. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
5. Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer
6. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting
7. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer
8. Evaluation of angiogenesis in non-small cell lung cancer: Comparison between anti-CD34 antibody and anti-CD105 antibody
9. Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31
10. High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression
11. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer
12. Prognostic significance of tumor vascularity
13. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study
14. The vascularity of primary cutaneous melanoma
15. The vascularity of cutaneous melanoma: A quantitative histological study of lesions 0.85-1.25 mm in thickness
16. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin
17. Extent of vascularization as a prognostic indicator in thin (<0.76 mm) malignant melanomas
18. Vascularity and prognosis of metastatic melanoma
19. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma
20. Relation of neovascularisation to metastasis of non-small-cell lung cancer
21. Tumor angiogenesis in human lung adenocarcinoma
22. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer
23. Prognostic value of angiogenesis in operable non-small cell lung cancer
24. Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence
25. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer
26. Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer
27. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis
28. Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer
29. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer
30. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma
31. Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer
32. The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients
33. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: A prospective study
34. Neoangiogenesis and p53 protein in lung cancer: Their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression
35. Neovascularization in clinical stage A testicular germ cell tumor: Prediction of metastatic disease
36. Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis
37. Tumor vascularity: A histological measure of angiogenesis and hypoxia
38. Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study
39. Tumor-associated angiogenesis in prostate cancer
40. Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma
41. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity
42. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate
43. Assessment of the vascularization in prostatic carcinoma: A morphometric investigation
44. Microvessel density in core biopsies of prostatic adenocarcinoma: A stage predictor?
45. Independent prognostic importance of microvessel density in clinically localized prostate cancer
46. Microvessel density in prostate cancer: Lack of correlation with tumor grade, pathologic stage, and clinical outcome
47. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas
48. Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis
49. Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression
50. Morphometric microvascular characteristics predict prognosis in superficial and invasive bladder cancer
51. p53 and microvessel density in primary resection specimens of superficial bladder cancer
52. Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma
53. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus
54. Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy
55. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma
56. Association of tumour vasculature with tumour progression and overall survival of patients with non-early gastric carcinomas
57. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer
58. Tumor angiogenesis and rectal carcinoma
59. Microvessel quantification and its possible relation with liver metastasis in colorectal cancer
60. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma
61. Angiogenesis in colorectal tumors: Microvessel quantitation in adenomas and carcinomas with clinicopathological correlations
62. Tumor angiogenesis in lymph node-negative rectal cancer: Correlation with clinicopathological parameters and prognosis
63. Is tumour angiogenesis a prognostic factor in patients with colorectal cancer and no involved nodes?
64. The prognostic significance of tumor vascularization in patients with localized colorectal cancer
65. Prognostic significance of the microvascular count in colorectal cancer
66. A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies
67. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma
68. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis
69. Angiogenesis in chronic myeloproliferative diseases
70. Angiogenesis in hematologic malignancies
71. Angiogenesis in multiple myeloma
72. What is the evidence that tumors are angiogenesis dependent?
73. Reciprocal paracrine interactions between tumour cells and endothelial cells: The 'angiogenesis progression' hypothesis
74. Tumour vascularity and proliferation: Clear evidence of a close relationship
75. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
76. The histological structure of some human lung cancers and the possible implications for radiotherapy
77. NIR reflection measurements of hemoglobin and cytochrome aa3 in healthy tissue and tumors. Correlations to oxygen consumption: Preclinical and clinical data
78. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
79. Angiogenesis in pituitary adenomas and the normal pituitary gland
80. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer
81. The hallmarks of cancer
82. Towards prediction and modulation of treatment response
83. Theory and practice of predictive assays in radiation therapy
84. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays
85. Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy
86. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice
87. Cancer: Looking outside the genome
88. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth pleiotrophin in human primary breast cancer and its relation to angiogenesis
89. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy
90. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression
91. The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus
92. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival
93. Platelet-derived endothelial cell growth factor is not implicated in progression of cervical cancer
94. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours
95. Effect of p53 status on tumor response to antiangiogenic therapy
96. Clinical link between p53 and angiogenesis in lung cancer
97. Predictive power of the tumor oxygenation status
98. Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen
99. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes
100. Vascular permeability factor/vascular endothelial growth factor: A multi-functional angiogenic cytokine
101. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
102. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha
103. The von Hippel-Lindau tumor suppressor gene
104. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
105. Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies
106. Angiogenesis inhibitors in clinical development for lung cancer
107. Antitumor activity of thalidomide in refractory multiple myeloma
108. Thalidomide-a revival story
109. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
110. The onset and extent of genomic instability in sporadic colorectal tumor progression
111. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
112. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
113. Cancer: The evolved consequence of a destabilized genome
114. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDCF-B and VEGF
115. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
116. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis
117. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39
118. Genes expressed in human tumor endothelium
119. VEGFs, receptors and angiogenesis
120. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
121. Mechanisms of angiogenesis and arteriogenesis
122. Angiogenesis inhibition: A review
123. Combined effects of angiostatin and ionizing radiation in antitumour therapy
124. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin
125. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
126. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
127. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy
128. Cell resensitization during protracted dosing of heterogeneous cell populations
129. Anti-angiogenesis therapy: Concepts and importance of dosing schedules in clinical trials
130. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
131. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
132. Metronomic scheduling: The future of chemotherapy?
133. Chemotherapeutic drugs-more really is not better
134. High-time chemotherapy or high time for low dose
135. Antiangiogenic scheduling of lower dose cancer chemotherapy
136. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor